{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:07:56Z","timestamp":1778857676249,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ajkd.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T04:00:29Z","timestamp":1389412829000},"page":"363-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults"],"prefix":"10.1053","volume":"63","clinical-trial-number":[{"clinical-trial-number":"isrctn07757494","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct01180036","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrey V.","family":"Cybulsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hladunewich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Bargman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Humar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bitzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zappitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Dart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherry","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maury","family":"Pinsk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Muirhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2013.12.001_bib1","first-page":"S1","article-title":"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Metabolic Bone Disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2013.12.001_bib2","first-page":"S1","article-title":"KDIGO Clinical Practice Guideline for the Care of Renal Transplant Recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib3","first-page":"337","article-title":"KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib4","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1053\/j.ajkd.2013.12.001_bib5","first-page":"279","article-title":"Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2013.12.001_bib6","first-page":"S1","article-title":"KDIGO Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"109","year":"2008","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1053\/j.ajkd.2013.12.001_bib7","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1053\/j.ajkd.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","article-title":"Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: management of nephrotic syndrome in children","volume":"63","author":"Samuel","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib9","first-page":"CD001537","article-title":"Interventions for minimal change disease in adults with nephrotic syndrome","volume":"1","author":"Palmer","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1053\/j.ajkd.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A\u00a0randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrneph.2012.35","article-title":"Pathogenesis of membranous nephropathy: recent advances and future challenges","volume":"8","author":"Ronco","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy","volume":"27","author":"McQuarrie","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9868","key":"10.1053\/j.ajkd.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2013.12.001_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2014a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ki.2011.399","article-title":"Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion","volume":"81","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2013.12.001_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update","volume":"16","author":"Appel","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib22","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl C","key":"10.1053\/j.ajkd.2013.12.001_bib25","doi-asserted-by":"crossref","first-page":"5C","DOI":"10.1155\/2007\/910831","article-title":"Management of chronic hepatitis B: consensus guidelines","volume":"21","author":"Sherman","year":"2007","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"10.1053\/j.ajkd.2013.12.001_bib26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2013.12.001_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","article-title":"UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients","volume":"35","author":"Ramachandran","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl C","key":"10.1053\/j.ajkd.2013.12.001_bib28","doi-asserted-by":"crossref","first-page":"25C","DOI":"10.1155\/2007\/138245","article-title":"Management of chronic hepatitis C: consensus guidelines","volume":"21","author":"Sherman","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib29","unstructured":"Montaner J; for the BC Centre for Excellence in HIV\/AIDS. Antiretroviral treatment of adult HIV infection. http:\/\/www.cfenet.ubc.ca\/sites\/default\/files\/uploads\/BCCfE%20Adult%20Therapeutic%20Guidelines_Jan2011.pdf. Accessed June 7,\u00a02012."},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib30","first-page":"534","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney\u00a0Int"},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2013.12.001_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ki.2011.126","article-title":"Validation of the Oxford classification of IgA nephropathy","volume":"80","author":"Herzenberg","year":"2011","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2013.12.001_bib33","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.2215\/CJN.02890311","article-title":"Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation","volume":"6","author":"Katafuchi","year":"2011","journal-title":"Clin J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2013.12.001_bib34","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2215\/CJN.11521210","article-title":"Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the Oxford classification","volume":"6","author":"Shi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00467-011-2061-0","article-title":"Validity of the Oxford classification of IgA nephropathy in children","volume":"27","author":"Shima","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2013.12.001_bib36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrneph.2010.123","article-title":"Pathology: Oxford IgA nephropathy classification: valid for children?","volume":"6","author":"Yamamoto","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2013.12.001_bib37","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2013.12.001_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2013.12.001_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.03190906","article-title":"Microalbuminuria and cardiovascular disease","volume":"2","author":"Weir","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2013.12.001_bib41","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2013.12.001_bib42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2013.12.001_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2013.12.001_bib45","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib46","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2013.12.001_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2013.12.001_bib48","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/ndt\/gfn161","article-title":"Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy","volume":"23","author":"Lv","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"21","key":"10.1053\/j.ajkd.2013.12.001_bib49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ndt\/gfn454","article-title":"Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial","volume":"24","author":"Ferraro","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib51","doi-asserted-by":"crossref","first-page":"c16","DOI":"10.1159\/000210570","article-title":"Vasculitic IgA nephropathy: prognosis and outcome","volume":"112","author":"Pankhurst","year":"2009","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"10.1053\/j.ajkd.2013.12.001_bib52","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2013.12.001_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.12.001_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2013.12.001_bib55","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2013.12.001_bib56","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib57","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/0961203309356292","article-title":"Practice pattern variation in oral glucocorticoid therapy after induction of response in proliferative lupus nephritis","volume":"19","author":"Walsh","year":"2010","journal-title":"Lupus"},{"key":"10.1053\/j.ajkd.2013.12.001_bib58","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2013.12.001_bib59","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2013.12.001_bib60","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function. A subgroup analysis of the Aspreva Lupus Management Study","volume":"61","author":"Walsh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib61","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2013.12.001_bib62","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/art.22449","article-title":"Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis","volume":"56","author":"Grootscholten","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1053\/j.ajkd.2013.12.001_bib63","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","article-title":"Long term follow-up of a randomized controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis","volume":"71","author":"Arends","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib65","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib66","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib67","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"24","key":"10.1053\/j.ajkd.2013.12.001_bib68","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","article-title":"A\u00a0controlled study of short-term prednisone treatment in adults with membranous nephropathy\u2014collaborative study of the adult idiopathic nephrotic syndrome","volume":"301","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2310\/JIM.0b013e318204c965","article-title":"Systematic review and meta-analysis of immunosuppressant clinical trials in membranous lupus nephritis","volume":"59","author":"Swan","year":"2011","journal-title":"J\u00a0Investig Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib70","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","article-title":"Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients","volume":"41","author":"Moroni","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1053\/j.ajkd.2013.12.001_bib71","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/art.1780341210","article-title":"Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience","volume":"34","author":"Petri","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2013.12.001_bib72","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1053\/j.ajkd.2013.12.001_bib73","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ajkd.2013.12.001_bib74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib76","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib77","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib79","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2013.12.001_bib80","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2013.12.001_bib81","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.ajkd.2013.12.001_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.12.001_bib83","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.ki.5002395","article-title":"Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future","volume":"72","author":"Walsh","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2013.12.001_bib84","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-nuclear cytoplasmic antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib85","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/ard.2008.092429","article-title":"Deoxyspergualin in relapsing and refractory Wegener's granulomatosis","volume":"68","author":"Flossmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ajkd.2013.12.001_bib86","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1681\/ASN.2005080870","article-title":"Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement","volume":"17","author":"de Lind van Wijngaarden","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613015552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613015552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:20:51Z","timestamp":1759458051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638613015552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0272638613015552"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.12.001","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}